Navigation Links
Randomized Clinical Trial of OrbusNeich's Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
Date:10/11/2010

HONG KONG, Oct. 11 /PRNewswire/ -- OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in China.

The primary objective of the 180 patient, controlled study is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor® Sprint stent in patients with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months after implantation and 270 day angiographic Late Loss (LL). Patients enrolled in the study were split evenly between the control and test arms.

"Based on its unique design and healing technology, we believe that Genous has the potential to give physicians an additional option for treating patients," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial. "We are excited to complete enrollment in this study, which may bring further clinical support for the technology's use in China."

David Chien, vice chairman of OrbusNeich, added, "This first clinical study of Genous in China is significant in the full development of the technology. We look forward to seeing additional clinical support for the use of Genous in challenging cases, such as diabetic patients and those who cannot tolerate a year of dual antiplatelet therapy."

Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
2. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
3. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
4. Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
5. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
6. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
7. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
10. West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
11. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... CHAPEL HILL, N.C. , Aug. 29, 2014 /PRNewswire/ ... Opinion Leaders (KOLs) can be the difference between a ... struggle to effectively map and stratify KOL targets – ... to build the type of strong relationships upon which ... recent research, savvy pharma companies have identified internal inconsistencies ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM ... (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that ... recall to address a potential issue with a ... for the Axilla application of the SAM Junctional ...
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... Results Show Superior Decrease in Pain Scores Compared to ... presented the results of a six-month safety and efficacy ... at decreasing the pain of knee osteoarthritis (OA) at ... is superior to saline in decreasing pain at 26 ...
... First ever 24 hour oral liquid sustained release ... platform - eliminates the need to swallow pills ... and films- Upon approval will provide both liquid ... immediate release tabletSOUTH BRUNSWICK, N.J., May 13 ...
Cached Medicine Technology:Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain 2Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain 3Tris Pharma Announces Acceptance of Its First Two NDAs 2
(Date:8/29/2014)... According to the latest review published by DailyGossip.org, ... quickly, safely and naturally. The new method promises great efficiency ... too. , Daily Gossip writes in its Flat Belly ... patients how to eliminate the extra pounds, it will also ... comes to body modeling. , The method reveals some ...
(Date:8/29/2014)... 2014 The new review that can be ... a holistic system that will permanently eliminate the symptoms of ... tinnitus can achieve a cure in as fast as 30 ... in only about one week. , The Tinnitus Miracle ... such as mild hearing loss, pain in the ear and ...
(Date:8/29/2014)... Panic attacks are extremely difficult to deal with. ... and fear, which appears with no particular reason, affecting ... affecting relationships. , A panic attack can be caused ... patients can deal with. Anxiety, shortness of breath and ... is extremely important for sufferers, who need a fast ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Dr. ... his plan to rename his practice to Parsa Mohebi ... Restoration has served the needs of hair loss patients ... traveled to its centers in Los Angeles, Beverly Hills, ... surgical and non surgical treatments, many of which Dr. ...
(Date:8/29/2014)... According to a CNN article, entitled Medical ... new study found that those states who legalized medical ... decrease in the number of painkiller overdoses seen. By ... and comparing various states with and without legalized medical ... about a 25% decrease in painkiller prescription overdoses in ...
Breaking Medicine News(10 mins):Health News:Flat Belly Forever Review Exposes the Way to Eliminate Body Fat Easily 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3
... of Tamil Nadu has called for designational equality with ... ,According to the association, the move will not add ... it exempt the government doctors from performing their assigned ... has also requested the Government to look into the ...
... or reducing enlarged heart (left ventricular hypertrophy, LVH) reduces ... condition that can lead to stroke and heart failure.// ... patients, or 12 million Americans, have LVH and are ... the direct relationship between levels of LVH in patients ...
... has said that it will undertake the subjects of brain ... genetic changes that lead to cancer.// ,The agency has ... pinpoint hundreds or thousands of new genes involved in cancer, ... to treat it and tools to diagnose it. ,Acting ...
... that although the drug Voltaren is commonly used for treating ... of heart attack.// ,Voltaren’s active ingredient, dicolfenac has been ... of the American Medical Association. ,On surveying results for ... to increase the relative risk of heart attack and stroke ...
... According to a recent study, marijuana enhances the efficacy ... Americans are affected by this fatal viral infection. The ... can offer medical benefits in certain situations. ... hepatitis C therapy. This treatment prolongs for months and ...
... leading cardiologists in US is asking for an extensive study ... blood clots on the use of stents. // ... arteries, these drug eluting stents are had essentially eliminated short-term ... have suddenly have come under a cloud for possible late-term ...
Cached Medicine News:Health News:For High BP Patients, Preventing Enlarged Heart Decreases Risk of Atrial Fibrillation 2Health News:For High BP Patients, Preventing Enlarged Heart Decreases Risk of Atrial Fibrillation 3
SkinStation, powered by LHE, is Radiancys flagship product. A powerhouse by design, it incorporates todays most sought after applications all on one user-friendly system ....
Inquire...
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
... Normal and Hypergamma Controls are ... either agarose gels or Sebia's ... Our unique control manufacturing process ... the other serum components, presenting ...
Medicine Products: